Posts

Showing posts from August, 2022

Hidradenitis Suppurativa (HS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 Hidradenitis Suppurativa (HS) is a chronic skin disease that causes painful, boil-like lumps that form under the skin and often secrete pus and blood. In most cases, the cause of HS is unknown. Some HS cases have been associated with specific genes, including NCSTN, PSEN1, and PSENEN. ·        It is estimated that the prevalence of hidradenitis suppurativa (HS) is between 0.5 and 4% and may affect about 11 in 100,000 people in the US. Females are more likely to be affected than males. Thelansis’s “Hidradenitis Suppurativa (HS) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hidradenitis Suppurativa (HS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain,

Gastric Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 Gastric cancer is the fourth most common malignant disease in men and the fifth in women. Fibroblast growth factors (FGFs) bind to FGFR, which subsequently undergoes phosphorylation at intracellular tyrosine residues, leading to the activation of downstream signalling. FGFR2 protein overexpression was observed in about 30% of gastric carcinomas and was positively correlated with scirrhous cancer, a diffuse type, invasion depth, infiltration type and a poor prognosis. The amplification of FGFR2 has been evident in approximately 5-10% of gastric cancer patients. FGFR2 amplification occurs more frequently in diffuse-type gastric cancer. However, there was no association found of FGFR2 amplification with histological subtype. Thelansis’s “Gastric Cancer Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical pr

Pulmonary Sarcoidosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 

Alpha-1 Antitrypsin Deficiency (AATD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 Alpha-1 Antitrypsin Deficiency (AATD) is an autosomal codominant genetic condition that can result in serious lung disease in adults and/or liver disease at any age. AATD occurs when the blood is deficient in a protein called Alpha-1 antitrypsin, or AAT. The liver mainly produces AAT, which primarily protects the lungs from increased protease activity. The responsible gene, SERPINA1, is located on the long arm of chromosome 14 (14q31–32.3). According to Thelansis disease modeling data and literature review estimated, ~78000 patients with AATD in the United States in the year 2020. Thelansis’s “Alpha-1 Antitrypsin Deficiency (AATD) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential

Hemophagocytic Lymphohistiocytosis (HLH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 Hemophagocytic lymphohistiocytosis (HLH) is a condition in which the body produces an abnormally large number of activated immune cells (macrophages and lymphocytes). There are inherited, and non-inherited (acquired) causes of hemophagocytic lymphohistiocytosis (HLH). The acquired causes of HLH include infection, medications that suppress the immune system, autoimmune diseases, immunodeficiencies, certain types of cancer, and/or metabolic diseases. When HLH results from an inappropriate immune response to the Epstein-Barr virus or another viral illness, it may be due to a separate genetic condition called X-linked lymphoproliferative disease (XLP). XLP is caused by a mutation in the SH2D1A or XIAP gene and is inherited in an X-linked manner. Thelansis’s “Hemophagocytic Lymphohistiocytosis (HLH) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, com

Dry Eye Disease (DED) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
  Dry eye disease (DED) is a common chronic multifactorial ocular surface condition characterised by a failure to produce high-quality or sufficient amounts of tears to moisturise the eyes. Ageing, female sex, low humidity environments, systemic medications, and autoimmune disorders are all common risk factors for this syndrome. DED is classified as "dry eye with reduced tear production (aqueous deficient)" or "dry eye with increased evaporation of the tear film (hyper-evaporative type). Although 10% of people have aqueous deficient DED, more than 80% have hyper-evaporative type related to meibomian gland dysfunction (MGD) or a combination of the two. DED can significantly impact vision and quality of life because symptoms frequently interfere with daily activities such as writing, reading, or working on video display monitors. In the USA, the prevalence of Dry eye disease (DED) ranges from 5% to 7% in the adult population. Thelansis’s “Dry Eye Disease (DED)

Graves Ophthalmopathy – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 Graves ophthalmopathy (also known as Graves’ eye disease, Graves’ ophthalmopathy, Graves’ orbitopathy, TED) is an autoimmune inflammatory process that affects the periorbital and orbital tissue, closely associated with dysthyroidism. Thyroid eye disease is an autoimmune disorder. Usually caused by Graves’ disease, but it can also be associated with Hashimoto's thyroiditis. ·        It is estimated to be 16 per 100,000 women in the general population and 2.9 per 100,000 men in the general population. Thelansis’s “Graves Ophthalmopathy Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Graves Ophthalmopathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spa

Mesothelioma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
  Mesothelioma is a type of cancer that develops in the lining that covers the outer surface of some of the body's organs. It's usually linked to asbestos exposure. Mesothelioma mainly affects the lining of the lungs (pleural mesothelioma), although it can also affect the lining of the tummy (peritoneal mesothelioma), heart, or testicles. The four types of mesothelioma are identified by the location in the body where tumors develop. Pleural and peritoneal types of mesothelioma are the most common. Pericardial and testicular mesothelioma accounts for less than 2% of cases combined. According to Thelansis disease modeling data and literature review estimated, approximately 3350 cases of malignant mesothelioma are diagnosed annually. In the absence of occupational exposure to asbestos, the incidence is 0.1-0.25 per 100,000 population in both sexes. The risk of mesothelioma is increased in polluted areas by 2-10 fold compared with non-polluted areas. In

Emphysema – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 Emphysema is a lung disease that affects the alveoli (tiny air sacs). The alveoli become abnormally inflated in emphysema, damaging their walls and making breathing difficult. Emphysema is a type of COPD (chronic obstructive pulmonary disease). The cause of emphysema is usually long-term exposure to irritants that damage your lungs and the airways. ·        The prevalence of emphysema in the United States is approximately 14 million, which includes 14% white male smokers and 3% white male nonsmokers. The prevalence is slightly less for white female smokers and African Americans. Thelansis’s “Emphysema Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Emphysema treatment modalities options for

Bronchiectasis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 Bronchiectasis (Brong-ke-EK-ta-sis) is a condition where the airways become flabby and scarred due to damage. The airways are tubes that carry air in and out of your lungs. Damage to the walls of the airways usually is the cause of bronchiectasis. A lung infection may cause this damage. Severe pneumonia (nu-MO ne-ah), whooping cough or measles (uncommon in the United States due to vaccination), tuberculosis, and fungal infections are all examples of lung infections that can lead to bronchiectasis. Thelansis’s “Bronchiectasis Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Bronchiectasis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and Chi

Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 Head and neck squamous cell carcinoma (HNSCC) is the most common cancer arising in the head and neck region. The most common risk factors are smoking, excessive drinking, and human papillomavirus (HPV) infection. The outcomes for non-metastatic HNSCC remain very encouraging and continue to improve. Advances in radiation technology and techniques, better organ-preserving surgical options, and multidisciplinary treatment modalities have improved cure rates for locally advanced HNSCC patients. The advancement of immune checkpoint inhibitors has provided significantly better outcomes, but only a small proportion of patients obtain benefits. Most recurrent and/or metastatic HNSCC patients continue to have poor survival. This has led to the vigorous investigation of new biomarkers and biomarker-based therapies. ·        Head and neck cancer is the seventh most common cancer worldwide, accounting for 3% of all cancers, with approximately 900,000 new cases and half a million deaths annually

Acute Hepatic Porphyria (AHP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
 Acute Hepatic Porphyria (AHP) is a rare subgroup of porphyrias characterized by the occurrence of neurovisceral attacks with or without cutaneous manifestations. Acute hepatic porphyrias encompass four diseases: acute intermittent porphyria (the most common), variegate porphyria, hereditary coproporphyria, and hereditary deficit of delta-aminolevulinic acid dehydratase (extremely rare). Each acute hepatic porphyria results from a deficiency of one of the enzymes in the heme biosynthesis pathway. These deficiencies result in an accumulation of the precursors of porphyrins in the liver (delta-aminolevulinic acid, ALA, and porphobilinogen, PBG) and also, in the case of variegate porphyria and hereditary coproporphyria, an accumulation of porphyrins resulting in cutaneous manifestations. ·        In the United States, the prevalence of porphyria is approximately 1 in 25,000 individuals. The worldwide prevalence ranges from one in 500 to one in 50,000 individuals. ·        In most Euro

Cystic Fibrosis (CF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Image
  Cystic fibrosis (CF), a single-gene disease with autosomal recessive inheritance, is caused by a mutation in the CF gene aptly named the CFTR protein. The CFTR protein creates a chloride channel, which is essential for efficient mucus transport. Mutations in CFTR disrupt chloride secretion, water transport, and sodium reabsorption, leading to mucus hyper concentration and decreased mucociliary clearance. Dehydrated mucus secretions cause endobronchial infection with a narrow spectrum of distinctive bacteria and exaggerated inflammatory response, which results in the development of severe bronchiectasis rather than fibrosis and, eventually, respiratory failure. The first signs of CF are gastrointestinal and nutritional disorders. According to Cystic Fibrosis Foundation, about ~38,000 Americans, ~5,200 Canadians, and ~27,000 Europeans are living with CF. The disease is less common in other regions of the world. Thelansis’s “Cystic Fibrosis (CF) Market Outlook, Epidemiol